The Efficacy of Teriflunomide in Patients Who Received Prior Disease-Modifying Treatments: Subgroup Analyses of the Teriflunomide Phase 3 TEMSO and TOWER Studies

Multiple Sclerosis- United States

doi 10.1177/1352458517695468

Full Text

Abstract

Available in

Date

March 17, 2017

Authors

Karthinathan Thangavelu

Myriam Benamor

Philippe Truffinet

Paul W O’Connor

Publisher

SAGE Publications

Related search

Clinical Efficacy of Teriflunomide Over a Fixed 2-Year Duration in the TOWER Study

Multiple Sclerosis Journal - Experimental, Translational and Clinical

2018

English

Clinical Recommendations on the Use of Teriflunomide

Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

English

Teriflunomide Treatment Reduces B Cells in Patients With MS

Neurology: Neuroimmunology and NeuroInflammation

Neurology

2017

English

Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects

Therapeutic Advances in Neurological Disorders

Neurology

Pharmacology

2014

English

Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis

Multiple Sclerosis and Related Disorders

Medicine

Neurology

2016

English

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study

English

Tolerability and Discontinuation Rates in Teriflunomide-Treated Patients. A Real-World Clinical Experience

English

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis

English

Nd3 - Meta-Analysis of Real-World Adherence and Persistence of Maintenance Once- Or Twice-Daily Oral Disease-Modifying Drugs (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Multiple Sclerosis

English

Amanote Research

The Efficacy of Teriflunomide in Patients Who Received Prior Disease-Modifying Treatments: Subgroup Analyses of the Teriflunomide Phase 3 TEMSO and TOWER Studies

Multiple Sclerosis- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Clinical Efficacy of Teriflunomide Over a Fixed 2-Year Duration in the TOWER Study

Clinical Recommendations on the Use of Teriflunomide

Teriflunomide Treatment Reduces B Cells in Patients With MS

Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects

Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis

Efficacy and Safety of Sirukumab in Japanese Patients With Moderate to Severe Rheumatoid Arthritis Inadequately Controlled by Disease Modifying Anti-Rheumatic Drugs: Subgroup Analysis of a Phase 3 Study

Tolerability and Discontinuation Rates in Teriflunomide-Treated Patients. A Real-World Clinical Experience

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis

Nd3 - Meta-Analysis of Real-World Adherence and Persistence of Maintenance Once- Or Twice-Daily Oral Disease-Modifying Drugs (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Multiple Sclerosis